EpCAM nuclear localization identifies aggressive Thyroid Cancer and is a marker for poor prognosis

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Ralhan, Ranju ^a,b   Cao, Jun ^a   Lim, Terence ^a   MacMillan, Christina ^a   Freeman, Jeremy L ^a   Walfish, Paul G ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; BETA CATENIN; CELL ADHESION MOLECULE; TACSTD1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ANTIBODY SPECIFICITY; ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; ADENOCARCINOMA; ENZYME IMMUNOASSAY; METABOLISM; PATHOLOGY; SURVIVAL RATE; THYROID TUMOR;

ADENOCARCINOMA, PAPILLARY; ANTIGENS, NEOPLASM; BETA CATENIN; CELL ADHESION MOLECULES; CELL NUCLEUS; CYTOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; PROGNOSIS; SURVIVAL RATE; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955378388     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-331     Document Type: Article

References (43)

1. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Köchli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004, 86:207-13. 10.1023/B:BREA.0000036787.59816.01, 15567937.
2. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006, 94:128-35. 10.1038/sj.bjc.6602924, 2361083, 16404366.
3. Wenqi D, Li W, Shanshan C, Bei C, Yafei Z, Feihu B, Jie L, Daiming F. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol 2009, 135:1277-85. 10.1007/s00432-009-0569-5, 19294417.
4. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007, 171:386-95. 10.2353/ajpath.2007.070152, 1934518, 17600130.
5. Stingl J, Eaves CJ, Zandieh I, Emerman JT. Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat 2001, 67:93-109. 10.1023/A:1010615124301, 11519870.
6. Schmelzer E, Reid LM. EpCAM expression in normal, non-pathological tissues. Front Biosci 2008, 13:3096-100. 10.2741/2911, 17981779.
7. Trzpis M, Bremer E, McLaughlin PM, de Leij LF, Harmsen MC. EpCAM in morphogenesis. Front Biosci 2008, 13:5050-5. 10.2741/3063, 18508569.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-8. 10.1073/pnas.0530291100, 153034, 12629218.
9. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007, 445:106-10. 10.1038/nature05372, 17122772.
10. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-5. 10.1038/nature05384, 17122771.
11. Weismann P, Weismanova E, Masak L, Mlada K, Keder D, Ferancikova Z, Vizvaryova M, Konecny M, Zavodna K, Kausitz J, Benuska J, Repiska V. The detection of circulating tumor cells expressing E6/E7 HR-HPV oncogenes in peripheral blood in cervical cancer patients after radical hysterectomy. Neoplasma 2009, 56:230-8. 10.4149/neo_2009_03_230, 19309226.
12. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69:5627-9. 10.1158/0008-5472.CAN-09-0654, 19584271.
13. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O. Nuclear signaling by tumor-associated-antigen EpCAM. Nat Cell Biol 2009, 11:162-71. 10.1038/ncb1824, 19136966.
14. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, Fleuren GJ, Warnaar SO. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997, 139:1337-48. 10.1083/jcb.139.5.1337, 2140211, 9382878.
15. Münz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004, 23:5748-58. 10.1038/sj.onc.1207610, 15195135.
16. Reis EM, Ojopi EP, Alberto FL, Rahal P, Tsukumo F, Mancini UM, Guimarães GS, Thompson GM, Camacho C, Miracca E, Carvalho AL, Machado AA, Paquola AC, Cerutti JM, da Silva AM, Pereira GG, Valentini SR, Nagai MA, Kowalski LP, Verjovski-Almeida S, Tajara EH, Dias-Neto E, Bengtson MH, Canevari RA, Carazzolle MF, Colin C, Costa FF, Costa MC, Estécio MR, Esteves LI, Federico MH, Guimarães PE, Hackel C, Kimura ET, Leoni SG, Maciel RM, Maistro S, Mangone FR, Massirer KB, Matsuo SE, Nobrega FG, Nóbrega MP, Nunes DN, Nunes F, Pandolfi JR, Pardini MI, Pasini FS, Peres T, Rainho CA, dos Reis PP, Rodrigus-Lisoni FC, Rogatto SR, dos Santos A, dos Santos PC, Sogayar MC, Zanelli CF. Head and Neck Annotation Consortium. Large scale transcriptome analyses reveal new genetic marker candidates of head, neck, and thyroid cancer. Cancer Res 2005, 65:1693-9. 10.1158/0008-5472.CAN-04-3506, 15753364.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
18. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003, 15:78-83. 10.1097/00001622-200301000-00012, 12490766.
19. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006, 13:453-64. 10.1245/ASO.2006.05.042, 16474910.
20. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009, 16:17-44. 10.1677/ERC-08-0154, 2829440, 18987168.
21. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, Melillo RM, Fusco A, Bittner ML, Santoro M. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007, 67:10148-58. 10.1158/0008-5472.CAN-07-1887, 17981789.
22. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 2009, 69:1916-23. 10.1158/0008-5472.CAN-08-1693, 19223553.
23. Morin PJ. β-catenin signaling and cancer. Bioessays 1999, 21:1021-30. 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P, 10580987.
24. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of β-catenin. Curr Opin Genet Dev 2006, 16:51-9. 10.1016/j.gde.2005.12.007, 16377174.
25. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. β-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001, 158:987-96. 1850336, 11238046.
26. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simoes M. E-cadherin loss rather than β-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 2003, 42:580-7. 10.1046/j.1365-2559.2003.01642.x, 12786894.
27. Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, Namba H, Ito M, Abrosimov A, Lushnikov E, Sekine I, Yamashita S. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant β-catenin expression. Histopathology 2005, 47:248-56. 10.1111/j.1365-2559.2005.02218.x, 16115225.
28. Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Duñach M, Elliott BE, Höppener JW, Mulligan LM. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res 2008, 68(5):1338-46. 10.1158/0008-5472.CAN-07-6052, 18316596.
29. Ensinger C, Kremser R, Prommegger R, Spizzo G, Schmid KW. EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. J Immunother 2006, 29:569-73. 10.1097/01.cji.0000211303.52503.da, 16971812.
30. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 2007, 96:1013-9. 10.1038/sj.bjc.6603505, 2360124, 17325709.
31. Ralhan R, DeSouza LV, Matta A, Chandra Tripathi S, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. JProteome Res 2009, 8:300-9.
32. Li H, Pamukcu R, Thompson WJ. beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther 2002, 1:621-5.
33. Ishida K, Ito S, Wada N, Deguchi H, Hata T, Hosoda M, Nohno T. Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia. Mol Cancer 2007, 6:62. 10.1186/1476-4598-6-62, 2140063, 17922924.
34. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-90. 10.1126/science.275.5307.1787, 9065402.
35. Ogasawara N, Tsukamoto T, Mizoshita T, Inada K, Cao X, Takenaka Y, Joh T, Tatematsu M. Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer. Histopathology 2006, 49:612-21. 10.1111/j.1365-2559.2006.02560.x, 17163846.
36. Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S, Inoue M, Monden T, Ito F, Monden M. Beta-catenin expression in human cancers. Am J Pathol 1996, 148:39-46. 1861624, 8546224.
37. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J. Nuclear accumulation of beta-catenin is a common and early event during neoplasic progression of Barrett esophagus. Am J Clin Pathol 2000, 114:583-90. 10.1309/3QLC-5MF1-JYXU-A5XX, 11026105.
38. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003, 129:199-221.
39. Antolovic D, Galindo L, Carstens A, Rahbari N, Büchler MW, Weitz J, Koch M. Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol 2010, 10:35. 10.1186/1472-6750-10-35, 2868015, 20426872.
40. El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther 2010, 9(1):57-66. 10.1158/1535-7163.MCT-09-0675, 2806489, 20053761.
41. Raffel A, Eisenberger CF, Cupisti K, Schott M, Baldus SE, Hoffmann I, Aydin F, Knoefel WT, Stoecklein NH. Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol 2010, 162(2):391-8. 10.1530/EJE-08-0916, 20097833.
42. Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat 2009,
43. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010, 52(2):280-1. 10.1016/j.jhep.2009.10.026, 20006402.